Post Intensive Care Optimization Through Lifestyle Intervention
Launched by MAASTRICHT UNIVERSITY MEDICAL CENTER · Jan 8, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Post Intensive Care Optimization Through Lifestyle Intervention," aims to help survivors of intensive care units (ICUs) who are experiencing muscle weakness and other physical challenges months after their hospital stay. Despite improvements in treatment during their ICU stay, many patients struggle with ongoing health issues that can significantly impact their daily lives and overall quality of life. The study will explore how a combined approach of exercise and nutrition can improve health and physical function for ICU survivors who are 6 to 12 months post-discharge.
To participate in this trial, individuals must be at least 18 years old, have spent a minimum of 5 days in the ICU, and have experienced ongoing physical complaints. They should also be living independently and able to understand the study requirements. Participants will engage in a 20-week program focusing on exercise and nutritional support. It’s important to note that individuals with certain medical conditions or those currently taking other nutritional supplements may not be eligible. This study is not yet recruiting, but it represents an important step toward enhancing the recovery and well-being of ICU survivors.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged 18 years and older
- • Minimum ICU length of stay of 5 days and/or mechanically ventilated for a minimum of 2 days
- • Persistent physical complaints
- • Community-dwelling, living independently (non-assisted)
- • Mentally competent with a Mini-Mental State Examination (MMSE) score of ≥24
- • Willing to participate in a 20-week multimodal lifestyle intervention
- Exclusion Criteria:
- • Any medical condition that may interfere with the safety of the subjects during exercise or any condition that interferes with assessment of the outcome parameters, in the investigators' judgement in consultation with the responsible physician or treating physician/specialist. In case of a contra-indication for MRI (e.g., a pacemaker), subjects will be excluded from this measurement but not necessarily from the study.
- • Any medical condition or circumstance where supplementation with the nutritional supplement is potentially contra-indicated.
- • Known allergy to any of the ingredients present in the nutritional supplement.
- • Simultaneous use of other nutritional supplements during the study period (i.e., unwillingness to stop for the duration of the study).
- • Current participation in other scientific research that conflicts with this study (e.g. intervention studies or weight management studies).
- • No permission to request information from the general practitioner/treating specialist(s) about medical history, medication use.
- • Pregnancy.
About Maastricht University Medical Center
Maastricht University Medical Center (MUMC+) is a leading academic medical center in the Netherlands, renowned for its commitment to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, MUMC+ integrates cutting-edge scientific inquiry with clinical practice, focusing on a wide range of medical disciplines. The center emphasizes collaboration among multidisciplinary teams, fostering an environment that promotes excellence in patient care and the translation of research findings into clinical applications. MUMC+ is dedicated to improving health outcomes and enhancing quality of life through rigorous clinical investigations and the development of novel therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Maastricht, Limburg, Netherlands
Patients applied
Trial Officials
Lex B Verdijk, Dr.
Principal Investigator
Maastricht University
Luc JC van Loon, Prof. Dr.
Principal Investigator
Maastricht University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported